NICE rejects ustekinumab
The National Institute for Health and Care Excellence has issued final guidance that does not recommend ustekinumab for psoriatic arthritis, alone or in combination with methotrexate. The independent appraisal committee concluded that ustekinumab is less effective than tumour necrosis factor alpha inhibitors and is not a cost-effective option. Patients currently receiving ustekinumab can continue receiving the medicine until they and their clinicians consider it appropriate to stop.
Citation: The Pharmaceutical Journal URI: 11138677
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com